



Suppl. Fig. 15. Differential phenotypes of physiologic (donor-) and malignant hematopoietic (recipient-derived) cells. A Surface marker expression (ASAP-seq), gene scores, transcription factor motif activity and mitochondrial DNA (mtDNA) mutations in AML (recipient-) and physiologic donor-derived hematopoietic stem cell (HSC)-like cells in IST1. B Surface marker expression (ASAP-seq), gene scores, transcription factor motif activity and mitochondrial DNA (mtDNA) mutations in AML (recipient-) and donor-derived erythroid cells in IST1. C Chromatin accessibility of CD36 in AML / recipient- and donor-derived erythroid cells in IST1. D Surface marker expression (ASAP-seq), gene scores, transcription factor motif activity and mitochondrial DNA (mtDNA) mutations in AML (recipient-) and donor-derived monocytic cells in IST3. E Chromatin accessibility of HOXA-AS3 and HOXA10 (top) and CCL4L2, CCL3L3 and CCL3L1 (bottom) in AML (recipient) and donor-derived erythroid cells in IST3. F Surface marker expression of CD33 and CD16 in AML (recipient-) and donor-derived monocytic cells in IST3. G Surface marker expression (ASAP-seq), gene scores and transcription factor motif activity in AML (recipient-) and donor-derived T cells in IST4.